Duodopa — Net revenues
Products & Services · Net revenuesAbbVie Duodopa — Net revenues decreased by 4.2% to $92.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 14.8%, from $108.00M to $92.00M. Over 4 years (FY 2021 to FY 2025), Duodopa — Net revenues shows a downward trend with a -7.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption or successful patient retention for the therapy, while a decrease may signal increased competition, patent expiration, or a shift in clinical treatment standards.
Detailed definition
This metric represents the total gross sales of the Duodopa product line minus returns, allowances, and discounts. It re...
Peer comparison
Comparable to specific product-line revenue disclosures in other pharmaceutical companies, often categorized under specialty pharmacy or neurology segments.
abbv_segment_duodopa_net_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $127.00M | $127.00M | $128.00M | $121.00M | $120.00M | $110.00M | $107.00M | $118.00M | $117.00M | $118.00M | $115.00M | $115.00M | $113.00M | $111.00M | $108.00M | $96.00M | $97.00M | $96.00M | $92.00M |
| QoQ Change | — | +0.0% | +0.8% | -5.5% | -0.8% | -8.3% | -2.7% | +10.3% | -0.8% | +0.9% | -2.5% | +0.0% | -1.7% | -1.8% | -2.7% | -11.1% | +1.0% | -1.0% | -4.2% |
| YoY Change | — | — | — | — | -5.5% | -13.4% | -16.4% | -2.5% | -2.5% | +7.3% | +7.5% | -2.5% | -3.4% | -5.9% | -6.1% | -16.5% | -14.2% | -13.5% | -14.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's duodopa — net revenues?
- AbbVie (ABBV) reported duodopa — net revenues of $92.00M in Q4 2025.
- How has AbbVie's duodopa — net revenues changed year-over-year?
- AbbVie's duodopa — net revenues decreased by 14.8% year-over-year, from $108.00M to $92.00M.
- What is the long-term trend for AbbVie's duodopa — net revenues?
- Over 4 years (2021 to 2025), AbbVie's duodopa — net revenues has grown at a -7.1% compound annual growth rate (CAGR), from $511.00M to $381.00M.
- What does duodopa — net revenues mean?
- The total sales revenue generated from the Duodopa product line after accounting for returns and discounts.